Health Economics Global Congress 2015 Europe

SL51

Background Info


The pharmaceutical industry is in a state of flux and with many drugs going off-patent in 2015 affecting drugmakers’ billions of sales. With this change, manufacturers have to look at ways to reduce costs and improve profit margins whilst promising safety and efficacy of their medicines.
Health Economics Global Congress 2015 Europe provides a unique platform for business knowledge sharing and convergence of top tier government, hospitals, pharmaceuticals, biotechnology, non-profit organisations, as well as regional and local manufacturers to discuss and share on the macroeconomic factors, policies, issues and drivers that will steer pharmaceutical industry.

Who Will You Meet

  • Health Economics and Outcomes Research
  • Pricing and Reimbursement
  • Market Access
  • Patient Outcomes
  • Payer Relations/Evidence
  • Data Management/Analysis
  • Regulatory Affairs
  • Public/Government Affairs
  • Payers, HTA Officials and Physicians

Key Speakers

Will Dunlop

Will Dunlop, Head of Market Access, MUNDIPHARMA INTERNATIONAL, UK

Will heads up the Market Access team at Mundipharma International. In this role he leads on international strategic pricing and market access decisions to guide Board decision. This involves in-depth analysis of the R&D pipeline and assessing major licencing and joint venture opportunities with other pharmaceutical companies. Will and his team are also responsible for communicating health economic models and disease burden through peer reviewed publications and conference presentations. Will completed in 2011 his BA- Honours Degree, in Economics, Political Science and Philosophy at the University of Otago, Dunedin, New Zealand. He then obtained a scholarship to study for a Master of Economics degree at Monash University in Melbourne, which he completed in 2003. Will joined the consulting firm Charles River Associates in Canberra, Australia, before moving to London in 2005 where he worked for a health economics consultancy, M-TAG (now part of IMS). Will then spent two and half years at Merck Sharp & Dohme (MSD) as a Health Outcomes Manager where he worked on a number of successful health technology assessment (HTA) submissions in the areas of oncology, HIV and antibiotics. Will joined Mundipharma International in 2009.


Nicolas Sireau

Dr Nicolas Sireau is Chairman and CEO of the AKU SOCIETY

The AKU Society is a fast-growing patient movement, with formal patient groups in the UK, France, Italy, Germany, the Netherlands, Jordan, Belgium, Slovakia, North America and India. It is spearheading an international consortium of biotechs, pharma companies, universities, hospitals and clinical trial centres across Europe, the Middle East, Asia and North America. It works closely with the hospital and university in Liverpool. Dr Sireau is Co-founder and Chairman of Findacure (www.fi ndacure.org.uk), a new social enterprise that raises awareness into and helps patients with fundamental diseases: extreme and exceptional diseases that advance our understanding of medicine and help us discover potential new treatments (www.fi ndacure.org.uk). He is a committee member of Rare Disease UK, the national alliance of rare disease groups in the UK, and of the International Rare Disease Research Consortium (IRDiRC). He is also is a founding member of the Cambridge Rare Disease Network and a trustee of DNAdigest, a social enterprise that works on collaborative data cures for genetic diseases. He is a fellow of the Ashoka fellowship of social entrepreneurs and of the Royal Society of Arts. He is the editor of ‘Rare Diseases: Challenges and Opportunities for Social Entrepreneurs’ (Greenleaf, 2013) and co-editor of ‘The Rare Diseases Patient Group Handbook’ (forthcoming). He is co-founder of the Vincent Foundation for brain injury and a former non-executive Director of GenSeq, a bioinformatics company. Dr Sireau’s previous career was in international development, where he was CEO of SolarAid and Sunny Money, two award-winning non-profi t social enterprises that he set up. Sunny Money is now the largest distributor of solar lanterns in Africa. He has also written several books on international aid. Dr Sireau has a PhD in Social Psychology. His hobbies include writing novels and producing electronic music.


Dr Ayad Abdulahad

Dr Ayad Abdulahad, MB, ChB, MSc, PhD, FRCPath.

Senior Vice President, Medical Affairs & Health Economics, Astellas Pharma Europe, Ltd
Ayad is a UK trained physician specialised in Clinical Immunology, Haematology and Oncology. He treated the first patient in the World ever to receive a Therapeutic Antibody for Cancer.
Ayad More than 23 years of experience in the pharmaceutical industry, during which Ayad have built and lead Medical Affairs and Clinical Development occupying Global senior positions in leading pharmaceutical companies in the US and Europe. During this, he led Clinical Development and Medical Affairs teams, as well as playing a leading part in defining global strategy and a major role in the regulatory processes. Ayad has taken drugs to Market in Multiple Sclerosis. His therapeutic areas of expertise include, Autoimmune Diseases, Urology, Dermatology, Pain, Anti-Infectives, Immunology, Oncology, CNS including Multiple Sclerosis and Alzheimer’s disease, Transplantation and Hematology.


Alexander Natz

Dr. Alexander Natz, Secretary General, EUROPEAN CONFEDERATION OF PHARMACEUTICAL ENTREPRENEURS (EUCOPE), BELGIUM

Since 2009, Alexander Natz is Secretary General of the European Confederation of Pharmaceutical Entrepreneurs (www.eucope.org) in Brussels and works as lawyer in his own law firm in Düsseldorf (www.natz-law.com). From 2008 to 2013, he was Head of the Brussels Office of Bundesverband der Pharmazeutischen Industrie e.V. (BPI). Before, he has been a lawyer with Sträter Law Firm in Germany with a special focus on discount agreements and licensing of pharmaceuticals. Dr. Natz also was working in the field of competition law with the European Commission and the pharmaceutical industry. As research assistant at Duke University (USA) he has dealt with international pharmaceutical law. His doctorate was supervised by former judge at the European Court of Justice, Prof. Dr. Dr. Ulrich Everling.


Michael Schlander

Prof. Michael Schlander, Chairman and Scientific Director, INSTITUTE FOR INNOVATION & VALUATION IN HEALTH CARE (INNOVAL), GERMANY

Professor Michael Schlander is founder and chairman of the independent Institute for Innovation & Valuation in Health Care (InnoValHC), a non-profit, non-partisan scientific organization dedicated to research related to the utilization, effectiveness, efficiency, and quality of health care, with particular emphasis on novel approaches of service provision.
He has taught, and continues to teach, health economics and innovation management at the University of Heidelberg, Mannheim Medical Faculty (since 2007; previously at the University of Duisburg-Essen, Faculty of Medicine, 2005-2008, and at the University of Witten/Herdecke, Faculty of Medicine, 1996-2005), and at the University of Applied Economic Sciences Ludwigshafen, Germany (since 2002).
Prior to his full-time university appointment in 2002, he spent fifteen years in executive positions with international research-based pharmaceutical companies in Germany, Belgium, and the United States.
Before that, he had spent six years in experimental brain research and clinical neurology at German universities.


David Watson

David Watson, Director of Pricing and Reimbursement, ABPI

He is primarily responsible for leading the implementation of the 2014 Pharmaceutical Price Regulation Scheme (PPRS), the scheme covers the vast majority of branded medicines sold to the NHS and is negotiated by the ABPI on behalf of industry and the Department of Health. The scheme is now half way through its second year, and has involved the industry underwriting most of the growth in branded medicines, but in return for maintaining UK list prices, as well as a variety of commitments on access and uptake. David also leads currently on ABPI’s NHS partnership focus, therapy groups, and input to the Accelerated Access Review (AAR).
Previously David worked in consulting, focusing on global projects within the Pharma industry on brand marketing, launch planning and biosimilars.
David spent much of his career with Pfizer, where he held a variety of UK and European roles across the business. He led work in European markets to establish new sales channels. In 2007 David led the Direct to Pharmacy (DTP) initiative which resulted in Pfizer breaking away from the traditional UK medicines supply model.


Leeza Osipenko

Dr Leeza Osipenko, Associate Director, NICE Scientific Advice

Dr Leeza Osipenko, Associate Director, NICE Scientific Advice. Leeza joined NICE in 2012. She heads the Scientific Advice service and leads on a number of strategic and international initiatives across the Institute. She holds an Honorary Fellow post at the University of Warwick Medical School and represents NICE as a Chief Analyst at the Department of Health Analytical Directors of Arm’s Length Bodies (ALBs) group. Leeza works closely with EMA, MHRA, European HTA agencies and EUnetHTA. She completed her education in the US and holds a BA in Economics & International Affairs, MSc in Technology Management and a PhD in Systems Engineering. As Senior Research Fellow at University of Warwick she conducted economic evaluation of non-invasive prenatal diagnostic tests. In 2010 she became a Principle Economist at a London-based public sector consultancy, Optimity Matrix, where she led on projects for NICE, the European Commission and other public sector organisations. Leeza’s current research interests focus on methods development for health technology evaluation of innovative medicinal products.


Henrii De Ridder

Dr. Henrii De Ridder, Director-General, NATIONAL INSTITUTE FOR HEALTH AND DISABILITY INSURANCE, Belgium

Education- 1976 University Ghent – Doctor in the Medicine, Surgery and Obstetrics

Professional Experience
National Institute for Health and Disability Insurance
Function: Director-General of the Health Care Insurance department
Period: from 17/10/2005
Strategic Cells of different Ministers of Social Affairs & Public Health
Function: Assistant Director
Period : from 01/01/1997 till 16/10/2005
District Health Centre “De Sleep??? – Ghent
Function: general practitioner
Period : from 02/08/1976 till 31/12/2000


Alexander Carter

Alexander Carter, Health Economist, Faculty of Medicine, Department of Surgery & Cancer, IMPERIAL COLLEGE LONDON

Alex Carter is a health economist in the Centre for Health Policy at the Institute of Global Health Innovation, Imperial College London.
His research focuses on the economic impact of quality improvement programs in the NHS and draws on methods used for the economic evaluation of health care programs and other social science techniques. As part of the patient safety program, Alex’s PhD aims to assess the economic impact of a nationwide patient safety initiative, the National Reporting and Learning System (or NRLS). His PhD is supervised by Professor the Lord Ara Darzi.
Alex’s other academic interests include pharmaceutical economics and policy, the evaluation of eHealth and mobile health technologies, and the economic impact of surgical checklists used in care. Alex also co-leads the ‘Health Systems and Policy’ and ‘Financing Healthcare’ modules on the Masters in Health Policy and lectures on both.
Prior to joining the Centre, Alex worked in the United States and Europe as a consultant in the pharmaceutical industry and completed his Master’s degree in health policy and economics at the London School of Economics and Political Science.


Anne Marciniak

Anne Marciniak, Senior Director, International HEOR, ALLERGAN, UK

Anne is currently Senior Director, European HEOR with Allergan. She has 20-year experience in Market Access and Health Economics in the pharmaceutical industry, including Pfizer, Amgen and recently Daiichi-Sankyo. With her teams, she lead the Market Access strategy of multiple compounds in the European environment focussing on meeting the needs of payers at national, regional and local levels. She has hands-on experience in establishing strategies and leading their cross-functional execution, integrating all elements of product value in particular clinical and safety profile, health economics and price. She believe that through engagement of all partners involved in the delivery of health care including payers the best value will be achieved for patients and citizens ultimately financing care. She is a physician by training with qualification in Health Economics and Epidemiology.


Amanda Cole

Dr. Amanda Cole, Economist, OFFICE OF HEALTH ECONOMICS, UK

Amanda is an Economist at the Office of Health Economics (OHE), London. In this role she has worked on a variety of projects, many relating to health policy research around the collection and use of real world data to generate health economic evidence. In particular, she is interested in how health technology assessment (HTA) must adapt to the changing regulatory environment and demands for earlier access to medicines, and how HTA methods differ across treatment types. Before joining OHE in 2014, Amanda was a research fellow at the University of Birmingham where she also undertook her PhD in Health Economics, focussing specifically medical devices. She was involved in projects commissioned by the National Institute for Health and Care Excellence (NICE), and also conducted research on approaches to embedding health economic evaluation in the product development process.


Amer Omar

Dr. Amer Omar, Managing Director, MLA PHARMA LTD, UK

Dr. Amer Omar is the Managing Director and owner of a highly specialised Health Economics, Market Access and Clinical Development consultancy in the UK. He has more than 15 years’ experience in the industry as he held a variety of global leadership positions within various pharmaceutical, medical devices and FMCG companies.
Dr. Omar received his degree in veterinary medicine & surgery from Jordan University of Science and Technology (J.U.S.T); he also holds a Master degree in Molecular cardiology & Physiology from the University of Manitoba in Canada, and he gained various diplomas in business and health economics from the university Birmingham in the UK.
Originally beginning his career in the pharmaceutical industry in the Middle East, where he was influential in developing a new model for localised observational research and health economics modelling. His career then took him to Canada, US and Europe during which he held variety of senior positions within the pharmaceutical and medical devices industry. After settling in the UK, Dr. Omar establishes his own consultancy in the UK to support and help companies gaining access and reimbursement to global health systems. His main focus is to facilitate access of patients around the world to innovative drugs and devices that could saves millions of lives.
In his latest role as a managing director of MLA Pharma Ltd, Dr. Omar approaches his work with both a spirit of innovation and technical excellence. He successfully applies his medical and market access experience and health technology acumen to lead the client’s success in gaining product’s reimbursement approval ” It is not only the technical knowledge that gives us the edge in delivering a successful reimbursement submission for our client’s products, but rather the ability to think outside the box, and find new innovative ways of delivering these results” Dr. Omar says.


Marisa Miraldo

Dr. Marisa Miraldo, Associate Professor in Health Economics, Imperial College London

Marisa joined the Imperial College Business School and the Health Care Management Group as an Assistant Professor in Economics in 2008. In the past she has held academic appointments at the Centre for Health Economics and the Department of Economics and Related Studies both at the University of York. Marisa holds a PhD in economics from York University, a MSc in Economics and Finance from Universitat Pompeu Fabra, a Master of Arts in Economics from Université Catholique de Louvain and a first degree in economics from Universidade Católica Portuguesa. Marisa has developed expertise in public policy and pharmaceutical economics by having participated in research projects commissioned by the Department of Health focusing on topics such as competition and regulation in secondary and primary care, competition between public and private providers and the impact of public policy on Pharmaceutical firms’ strategies. She is particularly interested in regulation and competition in the health care sector and, more generally, in the public sector.


Patrick Mollon

Dr. Patrick Mollon, Director Global Patient Access IHC, NOVARTIS, SWITZERLAND

Patrick Mollon, MD, ESSEC MBA, MSc acquired his medical qualification in Lyon’s School of Medicine, France where he also gained a Masters Degree in Medical and Biological Sciences, including Pharmacology, Psychology and Medical Statistics. Prior to this, he received an MBA from the Superior School of Business and Administration and Economics (ESSEC) in Paris. He then worked as a Clinician, practicing General Medicine as well as being a Registrar in Emergency Medicine and Intensive Care in a University Teaching Hospital in Lyon, France. He started his Pharmaceutical Career in Pfizer Central Research as a Clinical Research Physician and then joined the Outcomes Research Division where he held a number of successive positions in the Product Development Group and the Medical division. He is currently Director, Global Health Economics and Outcomes Research at Novartis AG. Patrick has extensive experience in developing and implementing Health Economic strategies to support developmental compounds in a number of therapeutic areas, including Cardiovascular, Urology, Anti-Virals, leading the value identification and demonstration efforts for Market Access and Health Technology Assessment from a Global perspective . As such, he is leading the development of Patient Reported Outcomes tools, Health-Economic and Budget-Impact models, and Value Dossiers. Patrick has a number of publications in the area of Health-Economics and Outcomes Research, His main interests are in health-economic modelling methods and applications as well as patient-reported outcomes and decision-making.


Patrick Hopkinson, Executive Director WWHEOR Markets, BRISTOL-MYERS SQUIBB, UK

Patrick is Director of Market Access and External Affairs at Bristol Myers Squibb. In his role Patrick leads the key market access functions including Government Affairs, Communications, Pricing , Pharmacy & Distribution and Health Economics and Outcomes Research.
He manages the strategic and operational interfaces with UK HTA bodies (ie NICE, SMC and AWMSG), the NHS, Department of Health and Government. He represents BMS on a number of Industry bodies including the ABPI Value and Uptake Group and the American Pharmaceutical Group. He Chairs the ABPI Pharmaceutical Stroke Prevention in Atrial Fibrillation Initiative. Previously he was involved in a number of key Life Science policy initiatives including the ABPI/DoH Joint Working Task Force, the Office of Life Science Blue Print and the QIPP National Initiative.
Patrick joined BMS in Sept 2010. Previously he had spent 14 years at GSK in a variety of roles. He joined as a health economist in R&D, moved rapidly to a global strategic marketing role before moving to GSK UK. Following roles in sales management and marketing he was appointed Business Unit Director for the Specialist portfolio and finally appointed Director Portfolio and Partnership Marketing a key strategic department pioneering innovative projects with the NHS.
Prior to GSK, Patrick worked as a Clinical Pharmacist for 8 years specialising in Oncology and Palliative Care. Initially at Guys and St Thomas’ London and then Royal Berkshire Hospital Reading. He holds a Diploma in Clinical Pharmacy, a Masters in Health Economics and a MBA from Henley Management School.


Marije van Weelden, Director Market Access & Pricing Europe, FERRING PHARMACEUTICAL, SWITZERLAND

Marije van Weelden joined Ferring Pharmaceuticals in March 2014 as Director Market Access and Pricing Europe. She supports marketed products, as well as upcoming launches, and works closely with the Sr. Vice President, Head of Europe. Prior to Ferring, she worked with GlaxoSmithKline, Astellas and Shire Pharmaceuticals where she was responsible for respectively health economics, market access and real world data. Mrs. van Weelden is a Medical Doctor by training with an MSc in International Health Policy and Health Economics from the London School of Economics in London, UK, and holds an MBA from IMD in Lausanne, Switzerland.

Day 1


08:00-09:00 – Registration


09:00-09:10 – Chairperson’s Opening Remarks


09:10-09:50 – The System’s Outlook: The Global Business in a State of Flux and How to Meet These Challenges with Effective Strategies in the Near to Medium Term?

  • What are the drivers of the current situation adding demands to the healthcare system?
  • How can governments manage costs with the higher life expectancies?

Alexander Carter, Health Economist – Faculty of Medicine, Department of Surgery & Cancer, IMPERIAL COLLEGE LONDON, UK


09:50-10:30 – What Approaches Are Available in the Development of Health Economics Strategies?

  • What outcomes research activities and methodologies to ensure accurate results?
  • Why is health economic modeling critical to the demonstration of product value?

Anne Marciniak, Senior Director, International HEOR, ALLERGAN, UK


10:30-11:10 – Morning Break and Networking


11:10-11:50 – Maximising the Value of Early Engagement: How Can Early Engagement Between Manufacturers, HTA Assessors and Regulators Help Companies Develop Products More Efficiently Whilst Improving Quality?

Dr. Alexander Natz, Secretary General, EUROPEAN CONFEDERATION OF PHARMACEUTICAL ENTREPRENEURS (EUCOPE), BELGIUM


11:50-12:30 – The Role of Corporate Health Economics: How to Credibly Contribute to Commercial Success?

Professor Michael Schlander, Chairman and Scientific Director, INSTITUTE FOR INNOVATION & VALUATION IN HEALTH CARE (INNOVAL), GERMANY


12:30-13:10 – Spotlight Presentation


13:10-14:10 – Networking Lunch


14:10-14:50 – How Should Pharmaceutical Companies Fully Integrate Payer Strategy Into Drug Development – A Therapy Evaluation and Communication Tool

Will Dunlop, Head of Market Access, MUNDIPHARMA INTERNATIONAL, UK


14:50-15:30 – Managing the Team: What’s the Value in an Organised Team?

  • How should regional teams be lead to develop programs that positively impact sales and meet varied regional needs?
  • How can companies organise teams to maximise performance?

Panellists:

Adrian Harrington, Senior Manager – HEOR, DAIICHI SANKYO, GERMANY

Anne Marciniak, Senior Director, International HEOR, ALLERGAN, UK


15:30-16:20 – Tea Break and Networking


16:20-16:50 – The Economic Impact of Rare Diseases

  • How can policy makers balance costs and health outcomes?
  • Evaluate potential and real impact of new technologies in social costs and health outcomes

Dr. Nicolas Sireau, Chairman & CEO, AKU SOCIETY, UK


16:50-17:30 – Why RWE Matters to Payers: Incorporating RWE in Health Economic Analysis to Maximise Value

  • Why is RWE important in understanding product value, and what role can it play in managed entry agreements?
  • What are the issues and challenges?

Dr. Amanda Cole, Economist, OFFICE OF HEALTH ECONOMICS, UK


17:30 – Chairperson’s Closing Remark & End of Day 1

Day 2


08:00-09:00 – Registration


09:00-09:10 – Chairperson’s Opening Remarks


09:10-09:50 – Health Economics in Product Development

  • How can you develop global perspectives on products’ introductions and health economics requirements that create synergies across products and regions?
  • Early stage exploration of product value

Dr. Patrick Mollon, Director Global Patient Access IHC, NOVARTIS, SWITZERLAND


09:50-10:30 – The Reality of Market Access and the Role of Health Technology Assessment

  • How can you formulate strategic recommendations on long-term payer strategy including pricing, clinical positioning and required clinical evidence/trial design?
  • How HTA can provide a more certain route to market and raise the bar for new drugs entering the market?

Moderator:

Dr. Amer Omar, Managing Director, MLA PHARMA LTD, UK

Panellists:
Dr. Leeza Osipenko, Associate Director – NICE Scientific Advice, Centre for Health Technology Evaluation, National Institute for Health and Care Excellence (NICE), UK
Patrick Hopkinson, Executive Director WWHEOR Markets, BRISTOL-MYERS SQUIBB, UK
Marije van Weelden, Director Market Access & Pricing Europe, FERRING PHARMACEUTICAL, SWITZERLAND


10:30-11:10 – Morning Break & Networking


11:10-11:50 – How Economic Uncertainties Are Affecting Pharmaceutical Reimbursement Spending?

Marije van Weelden, Director Market Access & Pricing Europe, FERRING PHARMACEUTICAL, SWITZERLAND


11:50-12:30 – Pricing and Reimbursement: Changing Paradigms

Dr. Ri De Ridder, Director-General, NATIONAL INSTITUTE FOR HEALTH AND DISABILITY INSURANCE, BELGIUM


12:30-13:10 – Spotlight Presentation


13:10-14:10 – Networking Lunch


14:10-14:50 – UK Pharmaceutical Price Regulation Scheme (PPRS) 2014: How This Aims to Address the Issues of Uptake and Access in the UK?

David Watson, Director of Pricing and Reimbursement, ASSOCIATION OF THE BRITISH PHARMACEUTICAL INDUSTRY (ABPI), UK


14:50-15:30 – Moving on to Emerging Markets: With Companies Being More Dependent on Emerging Markets, What Are Some Steps that Will Drive Revenue for These Markets?

  • How can companies maximise their pricing and access in the medium to long term?

Dr. Amer Omar, Managing Director, MLA PHARMA LTD, UK


15:30-16:10 – Tea Break & Networking


16:10-16:50 – Topic to be confirmed

Dr. Pearl Gumbs, Senior HEOR Manager, DAIICHI SANKYO, GERMANY


16:50-17:30 – Future of Health Economics: What Lies Ahead?

  • Is the industry prepared and equipped to support in meeting the challenges presented?
  • How can stakeholders work together to ensure economic progress whilst continue to provide safe and efficacy products?

Dr. Marisa Miraldo, Associate Professor in Health Economics, Business School, IMPERIAL COLLEGE LONDON, UK


17:30 – Chairperson’s Closing Remark & End of Conference

Sponsors

ASSOCIATE SPONSORS

Partners


Media Partners
biocompare

Biocompare

Biocompare is the most comprehensive, in-depth, and objective website for life science product information. Thousands of scientists use Biocompare daily to quickly find the right product for their experiments rather than looking through multiple print catalogs. Visit www.biocompare.com to find the products you need, stay informed of new technologies, read product reviews, watch product videos, and keep up-to-date on life science news. For further information please visit:www.biocompare.com


pharma-voice

PharmaVOICE

PharmaVOICE magazine provides commentary about the challenges and trends impacting the life-sciences industry, covering a range of issues from molecule through market. PharmaVOICE’s more than 25,000 BPA-qualified subscribers are also kept abreast of the latest trends through additional media resources, including WebSeminars, Podcasts, Videocasts, and White Papers. For further information please visit: www.pharmavoice.com


evenbrite

Eventbrite

Bringing the world together through live experiences . We’re creating the world’s first marketplace for live experiences by developing the technology that lets anyone create, share and find new things to do. For further information please visit: www.eventbrite.co.uk


select-science

Select Science

SelectScience.net is the leading online product and application publication for laboratory scientists featuring the latest news, application articles, videos, product directory and product reviews. Membership is fast, free and provides access to all of the SelectScience services. SelectScience.tv is a unique video news channel for laboratory application and product information. For further information please visit: www.selectscience.net


pharmiweb

PharmiWeb.com

PharmiWeb.com is the leading industry-sponsored portal for the pharmaceutical sector. Supported by most of the leading pharmaceutical corporations, PharmiWeb.com provides dynamic real-time news, features, events listings and international jobs to industry professionals across Europe and the US. For further information please email: corporate@pharmiweb.com, PharmiWeb.com


bio-process

BioProcess International

BioProcess International™ is a monthly, controlled-circulation magazine devoted to the development, scale-up, and manufacture of biotherapeutics and biodiagnostics. Each issue provides the global industrial biotherapeutic community with up-to-date, peer-reviewed information detailing the business, politics, ethics, applications, products, and services required to successfully drive biopharmaceuticals, vaccines, and biodiagnostics through the development and manufacturing process. www.bioprocessintl.com


global-event-list

Global Events List

Global Events List is an online directory of scientific and medical events from around the world, brought to you by Elsevier. Attending these types of events facilitates the proliferation of scientific discoveries and the building of productive relationships. We hope to play our part by providing the most comprehensive, user-friendly, reliable, and high quality listing of events available. www.globaleventslist.elsevier.com


mc

Manufacturing Chemist Pharma

Manufacturing Chemist is among the longest established and most respected information sources in the global pharmaceutical manufacturing industry. Manufacturing Chemist reports on current and future trends in the global marketplace, including the latest developments in drug discovery, biotechnology, drug delivery, ingredients, processing technologies and equipment, packaging, business strategies and regulatory updates. – See more at: www.manufacturingchemist.com


fierce-pharma

FiercePharma

FiercePharma is the pharma industry’s daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products.www.fiercepharma.com


pharma-phorum

Pharma Phorum

pharmaphorum.com is the premier digital publication for thought leadership relating to the pharmaceutical industry. The news, opinions and insights published every day help industry executives better understand the broader healthcare landscape within which they operate, including regular contributions from their peers, innovative service providers, physicians, payers / policy makers, patient organisations and patients. www.pharmaphorum.com


pharma-file

Pharmafile

Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, and pharma service company listings. Site content is produced by our editorial team for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches. www.pharmafile.com


my-event-guru

My Event Guru

My Event Guru is an interactive portal that allows individuals and businesses to set up, market and promote events, sell tickets and collect RSVP’s, instantly process payments for events online, obtain feedback via sophisticated surveys and generate additional revenue by selling event content. 
Our mission is to be your comprehensive local business event resource. We strive to be the one-stop solution for anyone looking to promote their events, take advantage of our event tools, and generate additional revenue from event content. We are committed to helping you make and maintain local connections and relationships that will make a difference your business and your career. www.myeventguru.com


bioequip

Bio-Equip

Bio-equip is a professional website which provides the information of equipments, consumables, chemical reagents and experimental animals in life science. Our website which takes full advantage of the most up-to-date computer technologies and networks offers the most all-round and considerate service in the information of biology equipments for not only institutes, universities, labs in hospitals but also scientists in bio-engineering and bio-medicine industries and suppliers of lab equipments who would be exposed to comprehensive and well-timed market information to compare the different products in function and price and promote the development of scientific research and industry. www.bio-equip.cn


pharma-tech

Pharmaceutical-Technology.com

Pharmaceutical-technology.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production. Pharmaceutical-technology.com brings you the latest in industry projects and updates, along with the news, views and trends that leading professionals – from senior executives to manufacturing managers and heads of procurement – require to stay on top of their field. Our international scope allows us to examine all pharmaceutical markets closely, from biotechnology to therapeutics, vaccines and more.www.pharmaceutical-technology.com


conal

Conal

Conference Alerts is an online conference calendar for academics and professionals. Organizers post conference information on www.conferencealerts.com and subscribers receive alerts about conferences in their areas of interest via email. www.conferencealerts.com


conferize

Conferize

Conferize is the world’s biggest social platform for events. You’re invited.We connect the world of events with speakers, people and media from any industry. We help event organizers build communities, websites and mobile experiences to increase the quality and attendance of their events. www.conferize.com


all-conferences

AllConferences.com

Originally, AllConferences.com was created solely as a directory of conferences, but due to popular demand we are now offering other services. Currently these include:
• Featured Listings
• Advertising Opportunities
• Online Registration Services 
In the future we plan to offer even more services. If you have any requests or suggestions, 
we would love to hear from you. Just drop us an email here:www.allconferences.com